Pfizer, Moderna to Deliver Updated COVID-19 Vaccines to U.S. Government

Trending News 🌥️

The U.S. government has finalized plans to administer a booster campaign of updated COVID-19 vaccines in September. This campaign will deliver more than 175 million doses of updated COVID-19 vaccines to states, pharmacies, and other vaccination sites across the country. The Biden administration has contracted with vaccine manufacturers Pfizer($NYSE:PFE) and Moderna to purchase the redesigned COVID-19 shots. These updated vaccines have been designed to protect against the latest subvariants of the Omicron virus and the original COVID strain. It is expected that this booster campaign will have a positive effect on Pfizer’s market and earnings in the long term. The company has already announced new agreements to deliver 105 million doses of updated COVID-19 vaccine doses to the government. This increased demand for Pfizer’s products is expected to result in increased sales and profits for the company.

Price History

This comes as new variants of the virus continue to spread around the world. Pfizer’s stock opened at $48.40 on Tuesday and closed at $48.00. Moderna’s stock was up slightly on the news. Both companies are working on updated versions of their vaccines that are specifically tailored to target the new variants. The U.S. government has been stockpiling vaccines in anticipation of new variants, and it is unclear how many doses Pfizer and Moderna will be able to provide. However, the fact that they are both working on updated versions shows that they are committed to keeping up with the evolving pandemic.

VI Analysis

Pfizer is a global pharmaceutical company with a long history of success. The company’s fundamentals reflect its long-term potential, and the VI app makes it easy to see why Pfizer is a good investment. The company has a strong balance sheet, good cash flow, and a robust pipeline of new products. However, there are some risks to consider. Pfizer is heavily dependent on the U.S. market, which could be a problem if the economy weakens. The company also has a large amount of debt, which could put pressure on its earnings if interest rates rise.

For more details please visit Risk Rating.

Summary

The U.S. government has invested heavily in both companies in order to secure a supply of vaccines for its citizens. Both companies have been working on updated versions of their vaccines that are more effective against new variants of the virus. Pfizer is expected to deliver its updated vaccine by the end of March, and Moderna is expected to deliver its updated vaccine by the end of April.